Creatine
|
Basic information |
| Metabolite name | Creatine |
 | HMDB0000064 |
 |
C00300 |
 |
586 |
| Synonyms | creatine + total creatine |
| No. of studies | 68 |
|
Basic information |
| Metabolite name | Creatine |
| HMDB0000064 |
|
C00300 |
|
586 |
| Synonyms | creatine + total creatine |
| No. of studies | 68 |
|
Relationship between Creatine and depression (count: 68) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Down |
| Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Down |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Brain | CD-1 mouse | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Liver | CD-1 mouse | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Liver | CD-1 mouse | Down |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Liver | CD-1 mouse | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Up |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M478 | Type3 | ketamine group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M553 | Type2 | CUMS + venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of negative control treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M591 | Type1 | LPS group vs. control group | Plasma | CD-1 mouse | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M604 | Type2 | CUMS + PBR group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type2 | CUMS + Poria cocos group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M614 | Type2 | CUMS + aerobic training group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M614 | Type2 | CUMS + resistance training group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, validation cohort | Plasma | Human | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M797 | Type4 | remitter group change values vs. non-remitter group change values | Anterior cingulate cortex | Human | Up |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M918 | Type1 | methamphetamine group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |